Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose posttransplant cyclophosp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Essential Thrombocythemia
• Multiple Myeloma
• Myelodysplastic Syndrome
• Myelofibrosis
• Myelomonocytic Leukemia
• Myeloproliferative Disorders
• Plasma Cell Dyscrasia
• Plasma Cell Leukemia
• Plasma Cell Neoplasm
• Polycythemia Vera
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2022-11-03